Loading
A phase 2 trial of BCB-276 in diffuse midline glioma, h3 k27-altered, run by BrainChild Bio, Inc, now recruiting.
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). is a phase 2 interventional study registered as NCT07680439 by BrainChild Bio, Inc, with 75 participants planned, started 2026-08 and due to reach its primary completion in 2028-10. Interventions recorded: BCB-276. Conditions listed: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/